Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects Of Artificial Tears on Tear Lipid Films
NCT05705518Phase 4Completed
- Sponsor
- University of California, Berkeley
- Start
- Jan 2023
- Primary completion
- Sep 2023
- Modality
- Nanoparticles, Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of propylene glycol/hydroxypropyl guar nanoemulsion in dry eye disease (DED) (4 arms), sponsored by University of California, Berkeley. Primary endpoint: Tear Lipid Layer Thickness at 3 months. Started Jan 2023; status: completed.
02
Drugs
propylene glycol/hydroxypropyl guar nanoemulsion
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05705518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05705518.